2024年11月28日，国家医疗保障局最新公告显示，百时美施贵宝旗下全球首款口服酪氨酸激酶2（TYK2）变构抑制剂颂狄多 ® （氘可来昔替尼片）已正式 ...

11月28日，国家医疗保障局最新公告显示，全球首款口服酪氨酸激酶2（TYK2）变构抑制剂颂狄多®（氘可来昔替尼片）已正式纳入《国家基本医疗保险 ...

事后来看，百时美施贵宝赌对了，2022年9月Sotyktu获批上市，成为唯一一款没有黑框警告的JAK抑制剂，并成功带火了TYK2抑制剂赛道。 不过，百时美 ...

国家医疗保障局最新公告显示，浦东跨国企业——百时美施贵宝旗下全球首款口服酪氨酸激酶2（TYK2）变构抑制剂颂狄多（氘可来昔替尼片）已正式 ...

Biogen Inc. has identified non-receptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of cancer, autoimmune disease, cardiovascular disorders, fibrosis, inflammatory ...

Published in Nature Neuroscience, the study suggests that partially restraining TYK2 could be a strategy to reduce tau levels and toxicity. “Many studies have shown that the accumulation of tau ...

Alumis' lead drug, ESK-001, is a potential best-in-class TYK2 inhibitor for treating plaque psoriasis and immunological diseases in general., with phase 3 trial data expected in 1H2026.

Published in Nature Neuroscience, the study suggests that partially restraining TYK2 could be a strategy to reduce tau levels and toxicity. Previous studies showed that tau is chemically modified ...